Lung oncology Clinical Trials in Nashville, TN
As of June 2026, 90 paid clinical trials are recruiting for Lung oncology in Nashville, Tennessee. Lung oncology trials investigate EGFR, ALK, KRAS, and other driver-mutation targeted therapies alongside immunotherapy combinations for non-small cell, small cell, and mesothelioma studies. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
90 clinical trials for Lung oncology
·Clear filters·↓ Download CSVA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
DESTINY-PANTUMOUR04
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
A Study of LY4175408 in Participants With Advanced Cancer
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
A Study of DM001 in Patients With Advanced Solid Tumors
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
About research studies in Nashville
Nashville has approximately 1,421 recruiting research studies across a wide range of therapeutic areas. Tennessee is home to Vanderbilt University Medical Center and St. Jude Children's Research Hospital — world leaders in pediatric oncology and personalized medicine.
Top Research Study Locations in Nashville
Researchers run research studies in Nashville, TN at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Vanderbilt University Medical Center | Parkinson Disease, Colorectal Cancer, Obesity | 379 |
| SCRI Oncology Partners | Breast Cancer, Advanced Solid Tumor, Colorectal Cancer | 123 |
| Vanderbilt University/Ingram Cancer Center | Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Head and Neck Squamous Cell Carcinoma | 95 |
| Sarah Cannon Research Institute | Advanced Solid Tumor, Colorectal Cancer, Advanced Solid Tumors | 65 |
| Vanderbilt University | Breast Cancer, Cardiac Failure, Graft Rejection | 58 |
| Tennessee Oncology | Breast Cancer, Multiple Myeloma, Carcinoma, Non-Small-Cell Lung | 54 |
| Vanderbilt-Ingram Cancer Center | Breast Cancer, Colorectal Cancer, Endometrial Cancer | 41 |
| The Children's Hospital at TriStar Centennial | Malignant Solid Neoplasm, B Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 27 |
| Monroe Carell Jr. Children's Hospital at Vanderbilt | Hypertension, Acute Kidney Injury, Acute Myeloid Leukemia | 17 |
| Tennessee Oncology, PLLC | Advanced Solid Tumor, Breast Cancer, Metastatic Breast Cancer | 15 |
| Vanderbilt Breast Center at One Hundred Oaks | Metastatic Malignant Solid Neoplasm, Anatomic Stage IV Breast Cancer AJCC v8, Advanced Malignant Solid Neoplasm | 15 |
| Tennessee Valley Healthcare System Nashville Campus, Nashville, TN | Cardiovascular Disease, Acute Kidney Injury (AKI), Aging | 12 |
| TriStar Centennial Medical Center | Acute Lower Limb Arterial Occlusion, Acute Myeloid Leukemia (AML), Aortic Stenosis | 12 |
| Tennessee Retina, PC | Geographic Atrophy, Neovascular Age-Related Macular Degeneration (nAMD), AMD | 9 |
| Ascension Saint Thomas | Coronary Artery Disease, Mitral Regurgitation, Atrial Fibrillation, Postoperative | 8 |
| GSK Investigational Site | Neoplasms, Hypereosinophilic Syndrome, Multiple Myeloma | 8 |
| Vanderbilt Eye Institute | Macular Edema Secondary to Inflammation, Age-related Macular Degeneration (AMD), Diabetic Retinopathy | 8 |
| Vanderbilt Ingram Cancer Center | AL Amyloidosis, Adamantinomatous Craniopharyngioma, Advanced Solid Tumors | 8 |
| Sarah Cannon Research Institute (SCRI) Oncology Partners | Metastatic Solid Tumor, Ovarian Cancer, Advanced NRAS-Mutant Melanoma | 7 |
| Sarah Cannon Research Institute - Pharmacy | Gastroesophageal Junction Adenocarcinoma, Breast Neoplasms, Stomach Neoplasms | 7 |
| Urology Associates, P.C. | NMIBC, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Cancer of the Prostate | 7 |
| Autonomic Dysfunction Center/ Vanderbilt University Medical Center | Autonomic Failure, Multiple System Atrophy, Pure Autonomic Failure | 6 |
| Centennial Medical Center | Cardiovascular Diseases, Coronary Artery Disease, Heart Failure | 6 |
| Henry-Joyce Cancer Clinic | Colorectal Neoplasms, Multiple Myeloma, Breast Cancer | 6 |
| Meharry Medical College | ARDS, Cardiovascular Diseases, Cognitive Impairment, Mild | 6 |
Active & Upcoming Studies in Nashville (2026)
Recruiting trials in Nashville grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (591 active studies)
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy · Phase 2 · National Cancer Institute (NCI)
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · Phase 1 · Eli Lilly and Company
Cardiovascular (85 active studies)
- Improving Veteran Referral to Cardiac Rehabilitation · VA Office of Research and Development
- Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD) · Stanford University
Neurology & pain (66 active studies)
- Individual vs Co-Treatment in Acute Stroke Rehabilitation and Evaluation · Vanderbilt University Medical Center
- Cholinergic Deep Brain Stimulation for Alzheimer's Disease · Vanderbilt University Medical Center
Diabetes & metabolic (52 active studies)
- A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · Novo Nordisk A/S
- Transition to Ambulatory Bariatric Surgery (TABS) Trial · Vanderbilt University Medical Center
Eye & vision (21 active studies)
- A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated · Phase 1, Phase 2 · Boehringer Ingelheim
- Clinical Evaluation of Lifitegrast Ophthalmic Solution 5.0% in Dry Eye Disease Using In Vivo Confocal Microscopy · Phase 4 · Toyos Clinic
Mental health & behavior (13 active studies)
- Cognitive Enhancement in Recurrent Depression (The COG-D-R Study) · Vanderbilt University Medical Center
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
Vaccines (11 active studies)
- Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS · Phase 2 · Vanderbilt University Medical Center
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) · Phase 2 · Vanderbilt University Medical Center
HIV / STI (10 active studies)
- Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV · Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID)
- GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · Vanderbilt University Medical Center
Pediatric (10 active studies)
- Neonatal Platelet Transfusion Threshold Trial · NICHD Neonatal Research Network
- Project PAIR: Parent-implemented Articulation Intervention With Recast · Vanderbilt University
Common conditions studied in Nashville
- Breast Cancer (45 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Advanced Solid Tumor (33 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Colorectal Cancer (29 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Ovarian Cancer (26 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Advanced Solid Tumors (25 active studies). Recruiting Advanced Solid Tumors studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Multiple Myeloma (23 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Nashville
- Vanderbilt University Medical Center
- AstraZeneca
- National Cancer Institute (NCI)
- Vanderbilt-Ingram Cancer Center
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Tennessee are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Tennessee research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Nashville. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Nashville
Hipa.ai aggregates every recruiting study in Nashville from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Nashville?
There are approximately 1,421 recruiting clinical trials in Nashville, Tennessee listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Nashville pay participants?
Most recruiting trials in Nashville compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Nashville?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Nashville?
The most common conditions under active study in Nashville include Breast Cancer (45), Advanced Solid Tumor (33), Colorectal Cancer (29), Ovarian Cancer (26), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Nashville?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Nashville on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Nashville?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Nashville?
Recruiting research sites in Nashville include Vanderbilt University Medical Center, SCRI Oncology Partners, Vanderbilt University/Ingram Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Nashville right now?
The largest active categories in Nashville are Cancer & tumors (591), Cardiovascular (85), Neurology & pain (66). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.